Clinical Trial Update: CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update reports evaluation of CNCT19, an autologous CD19 CAR-T cell therapy, for autoimmune hemolytic anemia in patients after failur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• CNCT19 (CNCT19 cell therapy)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Autoimmune Hemolytic Anemia, Autologous CD19 CAR-T | Phase 1 | Status: ACTIVE_NOT_RECRUITING